Abstract
BACKGROUND: Pyoderma gangrenosum (PG) is an uncommon dermatosis with a limited evidence base for treatment.
OBJECTIVE: We sought to estimate the effectiveness of topical therapies in the treatment of patients with PG.
METHODS: This was a retrospective cohort study of UK secondary care patients with a clinical diagnosis of PG that was suitable for topical treatment (recruited between July 2009 and June 2012). Participants received topical therapy after normal clinical practice (primarily topical corticosteroids [classes I-III] and tacrolimus 0.03% or 0.1%). The primary outcome was speed of healing at 6 weeks. Secondary outcomes included the following: proportion healed by 6 months; time to healing; global assessment; inflammation; pain; quality of life; treatment failure; and recurrence.
RESULTS: Sixty-six patients (22-85 years of age) were enrolled. Clobetasol propionate 0.05% was the most commonly prescribed therapy. Overall, 28 of 66 (43.8%) ulcers healed by 6 months. The median time to healing was 145 days (95% confidence interval, 96 days to ∞). Initial ulcer size was a significant predictor of time to healing (hazard ratio, 0.94 [95% confidence interval, 0.88-1.00); P = .043). Four patients (15%) had a recurrence.
LIMITATIONS: Our study did not include a randomized comparator.
CONCLUSION: Topical therapy is potentially an effective first-line treatment for PG that avoids the possible side effects associated with systemic therapy. It remains unclear whether more severe disease will respond adequately to topical therapy alone.
Original language | English |
---|---|
Pages (from-to) | 940-949 |
Number of pages | 10 |
Journal | Journal of the American Academy of Dermatology |
Volume | 75 |
Issue number | 5 |
Early online date | 5 Aug 2016 |
DOIs | |
Publication status | Published - Nov 2016 |
Bibliographical note
AcknowledgementsWe thank the patients who participated in the STOP GAP trial and the hospitals, doctors, and nurses who ensured that the study was a success (the full list of contributors appears below). We also thank our independent oversight committees, who guided this work with professionalism and care. The Trial Steering Committee includes John Ingram, Calum Lyon, Sarah Meredith, Paul Mussell, Frank Powell, and Daniel Wallach. The Data Monitoring Committee includes Angela Crook, Alison McDonald, and Julie Schofield. The trial was managed by the Nottingham Clinical Trials Unit, the UK Dermatology Clinical Trials Network, and the Robertson Centre for Biostatistics and the Centre for Healthcare Randomised Trials (CHaRT) in Aberdeen. Research nurses and administrators were provided through the National Institute for Health Research (NIHR) Clinical Research Networks in England, CRC Cymru Research Network in Wales, and NHS Research Scotland (NRS) for Scotland. Writing assistance was provided by Dr Natasha Rogers, and additional statistical support in preparation of this paper was provided by Dr Sally Wilkes.
Keywords
- cohort
- corticosteroid
- pyoderma gangrenosum
- side effects
- tacrolimus
- topical therapy